BeOne Medicines stock: Morgan Stanley maintains USD 425 target
Published on 10/30/2026 at 02:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalystenblick und aktuelle Unternehmensdaten
- MarketBeat berichtet über eine bestätigte Overweight-Einstufung von Morgan Stanley.
- Ein Insiderverkauf erfolgte im Rahmen eines vorab geplanten Rule-10b5-1-Handelsplans.
- Die zuletzt gemeldeten Quartalszahlen übertrafen die Konsensschätzungen bei Umsatz und Ergebnis je Aktie.
BeOne Medicines stock was quoted at EUR 331.00 by Lang & Schwarz on October 29, 2026, at 11:00 p.m. Berlin time. The company remains in focus after Morgan Stanley reaffirmed an Overweight rating and a USD 425.00 price target, according to MarketBeat.
Morgan Stanley keeps a positive stance
The analyst view was reported in connection with a research note dated October 16. The rating and target are Morgan Stanley's assessment and do not represent a company forecast or a guaranteed share-price outcome. Investors should therefore distinguish the dated analyst opinion from the later market quote.
Insider transaction adds context
MarketBeat also reported that Xiaodong Wang sold 31,028 shares in a transaction dated October 27. The sale was executed under a pre-arranged Rule 10b5-1 trading plan, and the report said the shares were sold at an average price of USD 362.97. The filing-based transaction is separate from Morgan Stanley's research assessment.
Recent operating backdrop
BeOne Medicines last reported quarterly revenue of USD 1.71 billion and earnings per share of USD 2.05, according to the same MarketBeat report. Those figures exceeded the cited consensus estimates of USD 1.66 billion in revenue and USD 1.40 in earnings per share. The company focuses on discovering, developing, manufacturing and commercializing oncology medicines, including BRUKINSA and TEVIMBRA.
For investors, the combination of a positive analyst stance, a disclosed insider transaction and the latest reported results provides context, but it does not establish a trading recommendation. The Lang & Schwarz quote is a separate market observation and is not presented as a causal reaction to any individual announcement.
For a live view, see the real-time quote of BeOne Medicines stock.
The broader US market environment can be followed through the S&P 500 market overview.
More company-specific coverage is available in more news and analyses on BeOne Medicines stock.
BeOne Medicines company data
- Company: BeOne Medicines
- ISIN: US07725L1026
- Ticker: ONC
- Primary listing: Nasdaq
- Lang & Schwarz quote: EUR 331.00 on October 29, 2026, at 11:00 p.m. Berlin time
